Utilization & Barriers to Checkpoint Inhibitor Consolidation in Stage III NSCLC: Insights from US Academic Health System
The following is a summary of “Utilization and Factors Precluding Receipt of Checkpoint Inhibitor...
Read More
Search Results for: NSCLC
PD-L1 Copy Number Alteration: Immunotherapy Response in Advanced NSCLC
The following is a summary of “Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct...
Read More
Tumor Treating Fields vs Standard Therapy in Treatment-Resistant Metastatic NSCLC
Bookmark1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with...
Read More
Salvage Surgery Following First-Line Alectinib for ALK-Rearranged NSCLC: Perioperative Outcomes & Pathological Response
The following is a summary of “Salvage Surgery After First-Line Alectinib for...
Read More
Combo Immunotherapy With Durvalumab Effective for NSCLC
MONDAY, Sept. 25, 2023 (HealthDay News) — For patients with resectable non-small cell lung...
Read More